Viral Mucosal Reprogramming

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

NCT Number	NCT05331170
Lead Sponsor	The University of Texas Medical Branch, Galveston Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	Asthma, Allergic Rhinitis, Cat Allergy, Healthy
Enrollment	75 participants
Start Date	2023-04-27
Primary Completion	2027-05-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-01-28